Company Overview
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas, as well as develops a data analytics and artificial intelligence platform to integrate diverse data sets into actionable insights that support precision oncology, therapeutic development, and clinical decision-making. The company was formerly known as Plus Therapeutics, Inc. and changed its name to Cerenome, Inc. in August 2026. Cerenome, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Why Investors Should Care
Trades at a P/E of 0.9, below the sector median of 24.8.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -70.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -70.40% |
Stock Price Performance
| 1 Year: | -81.05% |
| 6 Months: | -64.00% |
| 3 Months: | -51.18% |
| 1 Month: | -29.50% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.65 · Neutral
P/E of 0.92 is below the sector median of 24.83 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 87.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CNSY Cerenome, Inc. PHARMA | 2.70 | 0.92 | $20.49M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 3.54M | 1.54M | 4.48M | 5.74M | 7.12M |
| Operating Income | - | -3.54M | -1.54M | -4.48M | -5.74M | -7.12M |
| EBITDA | - | -16.71M | 5.27M | -4.34M | -2.56M | -6.83M |
| Interest Expense | - | 548.00K | 0 | 0 | 3.06M | 17.00K |
| Pretax Income | - | -17.40M | 5.15M | -4.42M | -5.71M | -6.95M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -17.40M | 5.15M | -4.42M | -5.71M | -6.95M |
| Diluted EPS | - | -29.75 | 0.25 | -1.00 | - | -1.05 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 19.71M | 13.32M | 14.70M | 15.30M |
| Operating Income | - | -19.71M | -13.32M | -14.70M | -15.30M |
| EBITDA | - | -18.95M | -12.29M | -8.38M | -18.33M |
| Interest Expense | - | 711.00K | 395.00K | 3.72M | 3.61M |
| Pretax Income | - | -20.27M | -13.32M | -12.98M | -22.39M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -20.27M | -13.32M | -12.98M | -22.39M |
| Diluted EPS | - | -288.75 | -106.00 | -58.50 | -7.25 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 23.87M | 11.39M | 6.63M | 16.32M |
| Current Assets | - | 21.82M | 9.83M | 5.26M | 15.17M |
| Cash & Equivalents | - | 18.12M | 8.55M | 76.00K | 4.26M |
| Inventory | - | - | - | - | - |
| Receivables | 7.00K | - | 0 | 571.00K | 322.00K |
| Total Liabilities | - | 17.42M | 12.74M | 15.58M | 12.33M |
| Current Liabilities | - | 11.85M | 10.73M | 15.55M | 12.31M |
| Long Term Debt | 5.00M | 3.79M | - | - | - |
| Total Debt | - | 5.64M | 4.18M | 3.37M | 821.00K |
| Total Equity | - | 6.45M | -1.35M | -8.95M | 4.00M |
| Shares Outstanding | - | 89.60K | 180.91K | 246.19K | 5.56M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -12.97M | -12.85M | -10.55M | -20.77M |
| Investing Cash Flow | - | -759.00K | -160.00K | -4.11M | -854.00K |
| Financing Cash Flow | - | 13.45M | 3.44M | 6.19M | 30.31M |
| Capital Expenditure | - | -759.00K | -160.00K | -691.00K | -67.00K |
| Free Cash Flow | - | -13.73M | -13.01M | -11.24M | -20.84M |
| Net Change in Cash | - | -280.00K | -9.57M | -8.48M | 8.68M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -314.6% | 987.8% | 145.0% | -560.2% |
| ROCE % | - | -164.1% | -2,015.3% | 164.8% | -381.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 4.02% | 304.75K | $618.63K |
| 2 | Blackrock Inc. | 1.26% | 95.98K | $194.84K |
| 3 | Geode Capital Management, LLC | 1.00% | 76.16K | $154.59K |
| 4 | Vanguard Fiduciary Trust Co | 0.49% | 36.87K | $74.84K |
| 5 | Ashton Thomas Private Wealth, LLC | 0.45% | 34.31K | $69.64K |
| 6 | Citadel Advisors Llc | 0.34% | 25.60K | $51.96K |
| 7 | Northern Trust Corporation | 0.20% | 15.52K | $31.50K |
| 8 | Virtu Financial LLC | 0.20% | 15.34K | $31.15K |
| 9 | HRT Financial LP | 0.15% | 11.61K | $23.57K |
| 10 | Wells Fargo & Company | 0.08% | 6.16K | $12.50K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CNSY
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE9uRG1MSmdpQWt2SjZTOFlmQldpak5qTUxURmU0NVl5MVd6TXVxUWhQX21GN1dpbDBrUHVmWnZwRG5xbnZ1R2trWWVnY1ZNZEdF?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNM1NvZlhZclVvN2FuZkdrRkc0cm90dXl5QXJJMzJlbHJNMVZHYzhKdHNpdzFSc3VodUUwRndPb3ZkOU1KeGtNcEdnMkRQYmdvWEVqejhyVUJseE9nYmJGNmRTWlZrR2trM1JEMFVGYWZKUk4tRktueFZmM1VKV3Y5UWJyUVFiVU9VRzFScn…
Tangible book value per share of Cerenome, Inc. – NASDAQ:CNSY - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTVkOTRhNFR3STVSS1dSdVo3bi1kN3VNOC1pSnhYdHc5TEltTjFxdXBoNnVoNTRxU1BkdjJCZ2RzdHNPOF92X1cxcFlKVGY0VUtacURnclBvLTZfMVNxd0FvbWdzWE9oaGZ1dkJ1bkl5QmNIUkY4VmhiR1dhaGw4ZHVWZEZaTV9SYjhYeF…
CNSY | Cerenome, Inc. Common Stock Institutional Ownership - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiYkFVX3lxTFBSeV9ZZzcwZElPV2tlZzU4bjZHVnRBbEkyYjY1RDVqT3k2Wi04c1ZhS1RJWERFaVdyQnpwSWNrZG1CQmFPX1diOGxqcThZbnROTkszZFowZHJldHk2QVpDSkVn?oc=5" target="_blank">CNSY | Cerenome, Inc. Common Stock …
Cerenome will combine CNS cancer diagnostics, treatments and AI Aug. 3 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNWTdjbVlPMGxZUG1VaV9wcmpqbGdRRG5hUnNYWC11UzJIWThLbVpNbHRZVGFJc3RmLV9RQ0VMTVVDZnUzNDZwRTl2enZXNXFzU3RZa3lya0ppWFBzd1pXUjBOaFNYcy02dlpWeEVuakNHLWhuQ2xaTHlrcTUyejVfaVJOSlVFXzhzR1kwQV…
CNSY - Cerenome Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE85bDNaQ3N1SC11NDRfUXlYY3g4OXRmeHNIYUN6X2MyamVGNmk2NkUtZjJYLU5WNGtqRkRkbVc4YmhlMWRFS1E?oc=5" target="_blank">CNSY - Cerenome Inc Stock Price and Quote</a> <font color="#6…
CNSY — Frequently Asked Questions
What is the current share price of Cerenome, Inc. (CNSY)?
As of 2026-09-19 21:16 PDT, Cerenome, Inc. (CNSY) trades at $2.70 on NasdaqCM. Its 52-week range is $2.70 to $22.25.
What is the market capitalisation of CNSY?
Cerenome, Inc. (CNSY) has a market capitalisation of $20.49M on NasdaqCM.
What is the P/E ratio of CNSY?
CNSY trades at a trailing price-to-earnings (P/E) ratio of 0.92. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.33.
Is CNSY a good stock to buy?
This page provides a data-driven analysis of Cerenome, Inc. (CNSY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.